X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds from the financing will be used to evaluate the lead program, NTX-1175 (taplucanium) dry powder for inhalation. It is being evaluated in Phase II clinical trial studies for the treatment of Chronic Cough.
Lead Product(s): Taplucanium
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NTX-1175
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Arkin Bio Capital
Deal Size: $62.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 04, 2024
Details:
NTX-1175 is being developed to treat cough and has received priority review through the U.K.’s Medicines and Healthcare products Regulatory Agency, as NOC-100 has the potential to treat both chronic and acute cough.
Lead Product(s): NTX-1175
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NOC-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Catalent Pharma Solutions
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
First subject in a healthy volunteer Phase 1 trial of NOC-100, an inhaled formulation of NTX-1175. NTX-1175 is a novel small molecule Charged Sodium Channel Blocker (“CSCB”) being developed for cough.
Lead Product(s): NTX-1175
Therapeutic Area: Infections and Infectious Diseases Product Name: NOC-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
